Getagozumab

mAbexperimental

Clinical trial activity

2 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2020 (NCT04503733)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04505137Phase 1Sep 2, 2020CMAX Clinical Research, Gmax Biopharm Australia Pty Ltd., Metaclinical, Syneos Health
NCT04503733Phase 1Jul 1, 2020Central South University, Chinese Academy of Medical Sciences, Chongqing Medical University, Gmax Biopharm Australia Pty Ltd., Harvard University, Huazhong University of Science and Technology, Jiao Tong University, Ohio State University, Shantou University, The University of Texas, Dallas, University of California, Los Angeles
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gmax Biopharm Australia Pty Ltd.For profit2212020
Central South UniversityAcademic/Hospital1012020
Chinese Academy of Medical SciencesAcademic/Hospital1012020
Chongqing Medical UniversityAcademic/Hospital1012020
CMAX Clinical ResearchFor profit1012020
Harvard UniversityAcademic/Hospital1012020
Huazhong University of Science and TechnologyAcademic/Hospital1012020
Jiao Tong UniversityAcademic/Hospital1012020
MetaclinicalFor profit1012020
Ohio State UniversityAcademic/Hospital1012020
Shantou UniversityAcademic/Hospital1012020
Syneos HealthFor profit1012020
The University of Texas, DallasAcademic/Hospital1012020
University of California, Los AngelesAcademic/Hospital1012020
14 organizations
Page 1 / 1